Development and validation of a multivariable prognostic model in de novo metastatic castrate sensitive prostate cancer-Reference-Cited by-同舟云学术

Development and validation of a multivariable prognostic model in de novo metastatic castrate sensitive prostate cancer

Published:2022-07-05 Issue:1 Volume:26 Page:119-125
ISSN:1365-7852
Container-title:Prostate Cancer and Prostatic Diseases
language:en
Short-container-title:Prostate Cancer Prostatic Dis

Author:

Roy Soumyajit^ORCID,Sun Yilun,Wallis Cristopher J. D.^ORCID,Morgan Scott C.^ORCID,Grimes Scott,Malone Julia,Kishan Amar U.^ORCID,Mukherjee Dibya,Spratt Daniel E.^ORCID,Saad Fred^ORCID,Malone Shawn^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Urology,Oncology

Link

https://www.nature.com/articles/s41391-022-00560-3.pdf

Reference35 articles.

1. Roy S, Morgan SC. Who dies from prostate cancer? An analysis of the surveillance, epidemiology and end results database. Clin Oncol. 2019;31:630–6. http://www.ncbi.nlm.nih.gov/pubmed/31130340.

2. Reese AC, Wessel SR, Fisher SG, Mydlo JH. Evidence of prostate cancer “reverse stage migration” toward more advanced disease at diagnosis: Data from the Pennsylvania Cancer Registry. Urologic Oncol: Semin Original Investig. 2016;34:335.e21–335.e28.

3. Cornford P, Bellmunt J, Bolla M, Briers E, de Santis M, Gross T, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71:630–42. https://pubmed.ncbi.nlm.nih.gov/27591931/

4. Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N. Engl J Med. 2017;377:352–60. https://doi.org/10.1056/NEJMoa1704174.

5. James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N. Engl J Med. 2017;377:338–51. https://doi.org/10.1056/NEJMoa1702900.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Outcomes and Risk Stratification in Patients With Metastatic Hormone-Sensitive Prostate Cancer Treated With New-Generation Androgen Receptor Signaling Inhibitors;Clinical Genitourinary Cancer;2024-10

2. De Novo Metastatic Prostate Cancer: Are We Moving toward a Personalized Treatment?;Cancers;2023-10-11

3. Prognostic Role of Dynamic Changes in Serological Markers in Metastatic Hormone Naïve Prostate Cancer;Cancers;2023-09-02

4. Efficacy of Systemic Treatment in Prostate Cancer Patients With Visceral Metastasis: A Systematic Review, Meta-analysis, and Network Meta-analysis;Journal of Urology;2023-09

5. Impact of Asian Race on Prognosis in De Novo Metastatic Prostate Cancer;Journal of the National Comprehensive Cancer Network;2023-07